[go: up one dir, main page]

AU2001294549A1 - Process and intermediates - Google Patents

Process and intermediates

Info

Publication number
AU2001294549A1
AU2001294549A1 AU2001294549A AU9454901A AU2001294549A1 AU 2001294549 A1 AU2001294549 A1 AU 2001294549A1 AU 2001294549 A AU2001294549 A AU 2001294549A AU 9454901 A AU9454901 A AU 9454901A AU 2001294549 A1 AU2001294549 A1 AU 2001294549A1
Authority
AU
Australia
Prior art keywords
intermediates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294549A
Inventor
Ann M. Eldridge
Johann Hiebl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2001294549A1 publication Critical patent/AU2001294549A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/22—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
    • C07C319/24—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides by reactions involving the formation of sulfur-to-sulfur bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
AU2001294549A 2000-09-12 2001-09-12 Process and intermediates Abandoned AU2001294549A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23178400P 2000-09-12 2000-09-12
US60231784 2000-09-12
PCT/US2001/028443 WO2002022554A1 (en) 2000-09-12 2001-09-12 Process and intermediates

Publications (1)

Publication Number Publication Date
AU2001294549A1 true AU2001294549A1 (en) 2002-03-26

Family

ID=22870636

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294549A Abandoned AU2001294549A1 (en) 2000-09-12 2001-09-12 Process and intermediates

Country Status (11)

Country Link
US (2) US6570024B2 (en)
EP (1) EP1322597B1 (en)
JP (1) JP4886961B2 (en)
AR (1) AR030612A1 (en)
AT (1) ATE555078T1 (en)
AU (1) AU2001294549A1 (en)
CY (1) CY1112871T1 (en)
DK (1) DK1322597T3 (en)
ES (1) ES2383792T3 (en)
PT (1) PT1322597E (en)
WO (1) WO2002022554A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2163256B1 (en) 2001-05-11 2015-09-02 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
KR101200133B1 (en) * 2004-06-01 2012-11-13 제넨테크, 인크. Antibody drug conjugates and methods
HUE030079T2 (en) 2004-09-23 2017-04-28 Genentech Inc Cysteine engineered antibodies and conjugates
CA2591148A1 (en) * 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
WO2008091701A2 (en) 2007-01-25 2008-07-31 Dana-Farber Cancer Institute Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
MX2009009782A (en) 2007-03-15 2010-09-10 Ludwig Inst Cancer Res Treatment method using egfr antibodies and src inhibitors and related formulations.
MX2010001757A (en) 2007-08-14 2010-09-14 Ludwig Inst Cancer Res Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof.
PT2896404T (en) 2009-06-04 2017-10-24 Novartis Ag Methods for identification of sites for igg conjugation
JP2012531212A (en) 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド Immunoconjugate and method for producing the same
EP3778917A3 (en) 2009-12-04 2021-06-09 F. Hoffmann-La Roche AG Multispecific antibodies, antibody analogs, compositions, and methods
WO2011075786A1 (en) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
CN107335062B (en) 2010-06-08 2021-09-24 基因泰克公司 Cysteine Engineered Antibodies and Conjugates
CN103562225B (en) 2011-05-27 2016-09-28 葛兰素集团有限公司 BCMA (CD269/TNFRSF17) binding protein
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
AU2014262566A1 (en) 2013-05-08 2015-11-12 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
WO2015073721A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
AU2015314826A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Cysteine engineered antibodies and conjugates
SI3956332T1 (en) * 2019-04-18 2023-05-31 Indena S.P.A. Diasteroselective process for the preparation of thiol- or disulfide-containing maytansinoid esters and intermediates thereof
US20250263495A1 (en) 2021-05-28 2025-08-21 Glaxosmithkline Intellectual Property Development Limited Combination Therapies for Treating Cancer
JP2024537863A (en) 2021-10-05 2024-10-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Combination Therapies for Treating Cancer
EP4698225A1 (en) 2023-04-21 2026-02-25 GlaxoSmithKline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (en) * 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab COUPLING OR TIOLATION REAGENTS
JPS61112042A (en) * 1985-07-31 1986-05-30 Wakunaga Seiyaku Kk Compound suitable as crosslinking reagent
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
JP3408158B2 (en) * 1998-07-17 2003-05-19 大日本製薬株式会社 Sultopride derivatives and anti-sultopride antibodies
US6573074B2 (en) * 2000-04-12 2003-06-03 Smithkline Beecham Plc Methods for ansamitocin production
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents

Also Published As

Publication number Publication date
JP2004509094A (en) 2004-03-25
WO2002022554A1 (en) 2002-03-21
EP1322597B1 (en) 2012-04-25
US6570024B2 (en) 2003-05-27
AR030612A1 (en) 2003-08-27
ES2383792T3 (en) 2012-06-26
US20020156318A1 (en) 2002-10-24
PT1322597E (en) 2012-06-01
JP4886961B2 (en) 2012-02-29
US20040014980A1 (en) 2004-01-22
EP1322597A4 (en) 2005-10-19
ATE555078T1 (en) 2012-05-15
US6884874B2 (en) 2005-04-26
EP1322597A1 (en) 2003-07-02
DK1322597T3 (en) 2012-07-02
CY1112871T1 (en) 2016-04-13

Similar Documents

Publication Publication Date Title
AU2001294549A1 (en) Process and intermediates
AU2001252973A1 (en) Biosensor and related method
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
EG23373A (en) Process and intermediates.
AU2002220932A1 (en) Chemical process and new intermediates
AU2001243394A1 (en) Compounds and methods
AU2001281965A1 (en) Novel 6-phenylphenanthridines
GB0123961D0 (en) Process and intermediates
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2001244470A1 (en) Assembly process
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AUPQ872300A0 (en) Compounds and methods
AU2001236718A1 (en) Bioreactor and related method
AU2001266176A1 (en) Methods
AU2002218440A1 (en) New process
AU2001278951A1 (en) Compounds and methods
AU2001272757A1 (en) Process for producing 5-fluorooxyindole and for producing intermediate therefor
AU2001237530A1 (en) Method
AU2001210572A1 (en) Ornament
AU2002235277A1 (en) Compounds and methods
AU2001241636A1 (en) Halotherapy method
AU2001267769A1 (en) Process
AU2002256556A1 (en) Sea-trosy and related methods
AU2001250536A1 (en) Methods